Breaking News, Financial News

WuXi PharmaTech 1Q11

Manufacturing outpaces lab services growth

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

WuXi PharmaTech 1Q Revenues: $93.6 million (+16%) 1Q Earnings: $18.2 million (+17%) Comments: Laboratory Services revenues grew 12% and Manufacturing Services were up 35% for the quarter. Manufacturing growth was driven by ramp-up of large-scale commercial manufacturing and increased demand for clinical trial materials. Gross margins in manufacturing rose from 19.9% to 26.7%, while Laboratory Services’ gross margins dropped from 41.4% to 39.6% due to higher labor costs, Chinese cu...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters